Background
==========

Neuroblastoma is a pediatric cancer that stems from immature precursors of the sympathetic nervous system with tumors arising in sympathetic ganglia or adrenal gland. Neuroblastoma tumors display high clinical variability, ranging from mainly favorable stage 1 tumors to aggressive stage 4 tumors with high lethality. There are several markers that correlate to either the disease's grade or outcome or both. Such markers are the expression of different Trk-receptors, degree of neural differentiation, or genetic aberrations such as 1p deletion, 11q deletion, gain of 17q, and amplification of the oncogene *MYCN*\[[@B1]\].

The phosphoinositide 3-kinase (PI3K)/Akt pathway participates in many biological processes such as proliferation, apoptosis, differentiation, metabolism and migration. The PI3K signaling cascade is initiated through activation of receptors with intrinsic tyrosine kinase activity, which leads to generation of the second messenger phosphatidylinositol (3,4,5)-triphosphate (PIP~3~), acting on downstream targets such as PI-dependent kinase (PDK1), integrin-linked kinase (ILK-1) or Akt/PKB. Type IA PI3K is a heterodimer composed of a regulatory subunit (p85α, p85β, p55α, p55γ or p50α) and a p110 catalytic subunit (p110α, p110β or p110δ). While p85β and p55γ is encoded by distinct genes, *PIK3R2* and *PIK3R3* respectively, p85α, p55α and p50α are different isoforms encoded by a single gene, *PIK3R1*.

Deregulation of the PI3K/Akt pathway is a recurrent feature in numerous human malignancies with a key role in cancer development, progression, and in resistance to chemotherapy. Over-activity is commonly caused by oncogenic activation of *PIK3CA*\[[@B2]\], over-stimulation caused by growth factors such as IGF-1, EGF or VEGF, or caused by loss of *PTEN* which is a negative regulator of Akt/PKB \[[@B3]\].

The contribution of PI3K/AKT in neuroblastoma carcinogenesis is not fully understood. Mutations in *PIK3CA* and *PTEN* are frequently reported in other malignancies but are rarely seen in neuroblastoma \[[@B4],[@B5]\]. Although a few mutations have been reported in *PIK3CD*\[[@B6]\], *PIK3CD* shows lower expression levels in aggressive neuroblastoma tumors compared to tumors with more favorable biology \[[@B7]\]. Furthermore, activation of AKT is seen in neuroblastoma with a correlation to outcome \[[@B8]\]. In addition, several genes in the PI3K-pathway are differentially expressed in aggressive neuroblastoma as compared with favorable neuroblastoma \[[@B9]\]. PI3K signaling affects MYCN protein stability through inactivation of GSK3β. Furthermore, inhibition of PI3K destabilized MYCN and prevented tumor progression in a murine model of neuroblastoma \[[@B10]\].

PI3K inhibition is considered to be one of the most promising targeted therapies for cancer, therefore the understanding of the molecular pathology of the individual tumors will be essential in matching patients with PI3K inhibitors of differing selectivity profiles. In this study we have investigated the different catalytic and regulatory subunits of Type IA PI3K, the phosphatase PTEN as well as AKT-phosphorylation in primary neuroblastoma tumors and cell lines. The differences in PI3K-isoform expression pattern shown between tumor subgroups indicates that patients may benefit from targeted therapy with different isoform specific kinase inhibitors.

Results
=======

Protein expression of the catalytic isoforms of the Type IA PI3-Kinase
----------------------------------------------------------------------

To explore the different isoforms of the type IA PI3-kinase (p110α, p110β and p110δ), we performed western blot on lysates from 22 primary neuroblastoma tumors and normal adrenal gland as well as six neuroblastoma cell lines and seven cancer cell lines of different origin (medulloblastoma, cervix, ovary, breast and colon). All catalytic isoforms were detectable in adrenal gland and also at variable degree in NB tumors (Figure [1](#F1){ref-type="fig"}A). p110α was detected in 14% of stage 1--2 (1/7), 50% of stage 3 (3/6) and 78% of stage 4 (7/9). Protein levels were significantly higher in stage 4 neuroblastomas as compared with stage 1--2 (p = 0.004) (Figure [1](#F1){ref-type="fig"}B). Protein levels were also higher in *MYCN* amplified tumors compared to non-amplified tumors. (p = 0.001) (Additional file [1](#S1){ref-type="supplementary-material"}). High levels of p110α were also detected in neuroblastoma cell lines in general, compared to non-neuroblastoma cell lines. In contrast to primary tumors there was a trend of higher p110α levels in non-amplified neuroblastoma cell lines (SK-N-AS and SK-N-F1) compared to cell lines with 2p-gain (SH-SY-5Y and NB69) or *MYCN* amplification (SK-N-DZ and SK-N-BE) (Figure [1](#F1){ref-type="fig"}C). p110β was detected in 71% of stage 1--2 (5/7), 66% of stage 3 (4/6) and 89% of stage 4 (8/9) (Figure [1](#F1){ref-type="fig"}A). No major difference in protein levels of p110β levels were detected when comparing stage 4 and stages 1--2 neuroblastomas (Figure [1](#F1){ref-type="fig"}B), although higher levels were seen in *MYCN* amplified tumors compared to non-amplified tumors (p \< 0.05) (Additional file [1](#S1){ref-type="supplementary-material"}). Cell lines originating from colon, breast, and ovaries had high levels of p110β compared to NB cell lines (p \< 0.05) (Figure [1](#F1){ref-type="fig"}C). The PI3K Type IA catalytic subunit p110δ was detected in 100% of stage 1--2 (7/7), 86% of stage 3 (6/7) and 67% of stage 4 (6/9) (Figure [1](#F1){ref-type="fig"}A) with overall protein levels of p110δ significantly lower in stage 4 as compared with stage 1--2 neuroblastoma (p = 0.04) (Figure [1](#F1){ref-type="fig"}B). No significant difference was seen when comparing *MYCN* amplified and non-amplified samples (Additional file [1](#S1){ref-type="supplementary-material"}).

![**Stage dependent expression of the different PI3K Type IA catalytic isoforms.A**) Protein levels of the different PI3K Type IA catalytical subunits were analyzed with western blot using two sets of primary neuroblastoma tumors. Abbreviations: AG, adrenal gland; MNA, MYCN amplification **B**) Relative quantification (RQ) of p110α, β and δ protein levels in primary tumors. Boxplot explanation; upper hinge of the box, 75^th^ percentile; lower hinge of the box, 25^th^ percentile; thick horizontal line within box, median. The whiskers are indicating range, open circles represent outliers while asterisks represent extremes. **C**) Western blot of cell lines with different origin show that cell lines of neuroblastic origin has high levels of p110α and low levels of p110β compared to non neuroblastic cell lines. Grading of MNA; no gain or amplification (−), gain (+), amplified (++).](1750-2187-8-4-1){#F1}

No significant difference was detected in correlation between age at diagnosis and protein levels of either PI3K Type IA catalytic subunit (Additional file [1](#S1){ref-type="supplementary-material"}).

Protein expression of the regulatory isoforms of the Type IA PI3-Kinase
-----------------------------------------------------------------------

The protein levels of the different isoforms of the type IA PI3-kinase regulatory subunits (p85α/β, p55α, p50α and p55γ), were evaluated in primary NB tumors and cell lines. All isoforms were detectable in adrenal gland and to various extents in neuroblastoma tumors (Figure [2](#F2){ref-type="fig"}A). Quantification of p85α/β levels showed no statistical difference comparing stage 1--2 and stage 4 (Figure [2](#F2){ref-type="fig"}B). Whereas the slightly lower levels seen in *MYCN*-amplified tumors compared to non-amplified was below statistical threshold (p \< 0.05) (Additional file [1](#S1){ref-type="supplementary-material"}). As judged by western blot, p85α/β were expressed at detectable levels in all cell lines (Figure [2](#F2){ref-type="fig"}C). The two shorter proteins isoforms p55α and p50α encoded by *PIK3R1* were detected at significantly lower levels in stage 4 compared to stage 1--2 neuroblastomas, p \< 0.001 and p \< 0.05 respectively (Figure [2](#F2){ref-type="fig"}B). p55α were detected in 5/6 (83%) and p50α in 4/6 (67%) of neuroblastoma cell lines (Figure [2](#F2){ref-type="fig"}C). The PI3K type IA subunit p55γ were detected in all cell lines except those of colorectal origin (Figure [2](#F2){ref-type="fig"}C) whereas a highly irregular pattern of protein expression was seen in primary tumors where protein levels ranged from undetectable to highly expressed (Figure [2](#F2){ref-type="fig"}A). No statistical difference in p55γ levels could be deducted when comparing stage 1--2 and stage 4 (Figure [2](#F2){ref-type="fig"}B), although a slightly higher level were seen in *MYCN* amplified compared to non-amplified tumors (p \< 0.05) (Additional file [1](#S1){ref-type="supplementary-material"}).

![**Stage dependent expression of the PI3K Type IA regulatory isoforms. A**) Protein levels of the regulatory subunits of Type IA PI3K: p85α/β, p55α, p50α and p55γ were analyzed with western blot using two sets of primary neuroblastoma tumors. Abbreviations: AG, adrenal gland; **B**) Relative quantification (RQ) of p85α/β, p55α, p50α and p55γ protein levels using Gapdh as endogenous control. Boxplot explanation; upper hinge of the box, 75^th^ percentile; lower hinge of the box, 25^th^ percentile; thick horizontal line within box, median. The whiskers are indicating range, open circles represent outliers while asterisks represent extremes. **C**) Protein levels of regulatory subunits in neuroblastoma cell lines (to the left), and cell lines of other origins (to the right).](1750-2187-8-4-2){#F2}

No significant difference was detected in correlation between age at diagnosis and protein levels of either PI3K Type IA regulatory subunit (Additional file [1](#S1){ref-type="supplementary-material"}).

Phosphorylation of Akt and correlation to PTEN levels
-----------------------------------------------------

Phosphorylation of Akt/PKB at serine 473 (S473) and threonine 308 (T308) were investigated by western blot in primary neuroblastoma tumors and analyzed in relation to protein levels of PTEN (Figure [3](#F3){ref-type="fig"}A). Levels of phosphorylated Akt/PKB (S473) (p = 0.05) and p-Akt/PKB (T308) (p \< 0.01) in stage 4 neuroblastoma were significantly higher compared to stage 1--2 tumors (Figure [3](#F3){ref-type="fig"}B). Also, phosphorylation of Akt/PKB at T308 was inversely correlated with levels of PTEN (p = 0.02, correlation coefficient; -0.492, Spearmans Rho) (Figure [3](#F3){ref-type="fig"}C) while PTEN levels showed no significant difference when comparing stage 1--2 with stage 4 (Figure [3](#F3){ref-type="fig"}B) or comparing *MYCN* amplified with non-amplified.

![**Phosphorylated Akt and correlation to PTEN. A**) Western blot of primary neuroblastoma tumors showing levels of p-Akt/PKB (S473), p-Akt/PKB (T308), Akt/PKB and PTEN. AG = adrenal gland. **B**) Levels of p-Akt/PKB (T308), p-Akt/PKB (S473) and PTEN in stage 1--2 (st 1--2) and stage 4 (st 4) neuroblastoma tumors. Relative quantification (RQ) was calculated using GAPDH as endogenous control. **C**) Correlation plot using Spearman Rho showing that levels of phosphorylated Akt/PKB (T308) are inversely correlated with protein levels of PTEN.](1750-2187-8-4-3){#F3}

Discussion
==========

The PI3K/Akt pathway is central for numerous cellular functions and it is frequently deregulated in human cancers. This pathway is also suggested to be an important player in neuroblastoma development where high mRNA expression of the PI3K catalytic isoform *PIK3CD* is associated with favorable disease \[[@B7]\], while activation of Akt/PKB is associated with poor prognosis \[[@B8]\]. These results look contradictory and warrant further evaluation of the different isoforms of PI3K in neuroblastoma, which was foreseen at the start of this study.

The tumor suppressor PTEN displays decreased activity in various cancers \[[@B3],[@B11]\] and has also been implicated in neuroblastoma even though mutations in *PTEN* are rare in this tumor \[[@B5]\]. One report shows PTEN levels to be decreased in undifferentiated neuroblastomas \[[@B12]\] which could be due to localization of *PTEN* to the chromosome region 10q, commonly deleted in a subset of neuroblastomas. We noted no significant difference in the PTEN protein levels when comparing different clinical features of aggressive disease in our material (Figure [3](#F3){ref-type="fig"}B). However, we did detect a higher degree of phosphorylation of Akt/PKB at Ser473 and Thr308 in aggressive neuroblastoma and a statistically significant correlation between high levels of p-Akt/PKB (T308) and low protein levels of PTEN (Figure [3](#F3){ref-type="fig"}C), indicating a direct effect of PTEN levels and Akt/PKB (T308) phosphorylation.

PTEN activity can be modulated by the p85 regulatory subunit of the Type IA PI3K \[[@B13]\], which also enhances the phosphatase activity of PTEN \[[@B14]\]. Consequently, lower levels of p85 could lead to decreased PTEN activity and hence, increase Akt/PKB phosphorylation. Decreased mRNA-expression of *PIK3R1* has previously been detected in aggressive neuroblastoma \[[@B9]\], although no significant difference in p85 protein levels were seen comparing stage 1--2 and stage 4 tumors (Figure [2](#F2){ref-type="fig"}B) along with only a modest decrease in *MYCN* amplified tumors (Additional file [1](#S1){ref-type="supplementary-material"}). This indicates that increased Akt/PKB phosphorylation seen in stage 4 tumors is caused by other means than p85-modulated PTEN activity.

It is noted that the two shorter *PIK3R1* encoded isoforms p55α and p50α are both detected at statistically significant lower levels in stage 4 tumors compared to stage 1--2. It has been shown that the regulatory subunits have separate functions and that changes in expression can affect PI3K/Akt signaling \[[@B15],[@B16]\]. One report suggests that p55α and p50α but not p85α are under transcriptional control of STAT3 \[[@B15]\], and a view of *STAT3* expression in the publically available R2 data base containing expression data from a set of 87 neuroblastoma tumors \[[@B17]\], show that STAT3 is significantly lower expressed in stage 4 tumors compared to stage 1 tumors (Additional file [2](#S2){ref-type="supplementary-material"}). However, to determine any causal relationship between p55α/p50α expression and STAT3 levels in a neuroblastoma context requires further investigation.

Oncogenic mutations of *PIK3CA,* encoding p110α, are common in various malignancies \[[@B2]\] but rare in neuroblastoma tumors \[[@B4]\], and there has been no reports of a difference in *PIK3CA*-mRNA expression between different stages of neuroblastoma. In a previous study no difference in *PIK3CA*-RNA-levels between different stages was found in this neuroblastoma material (Fransson et al. 2013). However, at the protein level we could detect significantly higher levels of p110α in aggressive tumors compared to stage 1--2 (Figure [1](#F1){ref-type="fig"}B), and also in MYCN amplified tumors compared to non-amplified. This indicates specific factors associated with aggressive disease could affect p110α stability or translation. An indication of this being a feature of neuroblastoma was the fact that the p110α protein levels were higher in neuroblastoma cell lines compared to the other tested cell lines (Figure [1](#F1){ref-type="fig"}C).

The p110β isoform has also been implicated in various malignancies \[[@B18],[@B19]\], but we could not detect any difference between stage 1--2 and stage 4 neuroblastoma p110β protein levels (Figure [1](#F1){ref-type="fig"}B), although slightly higher levels were detected in MYCN amplified tumors (Additional file [1](#S1){ref-type="supplementary-material"}). In contrast, both mRNA and protein levels from *PIK3CD*/p110δ are decreased in stage 4 neuroblastoma compared to stage 1--2 as described by us and others previously \[[@B7],[@B20]\].

Gene-targeting studies in mice have recently uncovered non-redundant roles for specific PI3K isoforms under normal physiological circumstances \[[@B21]\] but it is likely that different isoforms could have compensatory signaling in pathological conditions. Recent studies have shown that the α- and δ-isoform are downstream of receptor tyrosine kinases whereas p110β is activated through G-protein-coupled receptor signaling \[[@B22]\]. The pattern of high levels of p110δ in stage 1--2 and high levels of p110α in stage 4 (Figure [1](#F1){ref-type="fig"}B) indicate complementary functions of the α- and δ-isoform in Akt/PKB-signaling in neuroblastoma. However, the level of phosphorylated Akt/PKB is high in aggressive tumors where the level of p110α is high, indicating the importance of the α-isoform in advanced neuroblastoma.

Conclusions
===========

While the molecular mechanisms underlying neuroblastoma are slowly being uncovered, neuroblastoma continues to be fatal in many cases. In this study we show that the PI3K catalytic subunits p110α and p110δ are found in a pattern where p110α is detected at higher levels in aggressive tumors whereas p110δ is preferentially expressed in low stage tumors. Higher levels of p-Akt/PKB are associated with aggressive disease and indicate higher degree of activation of the PI3K/Akt pathway in these patients. The pattern of p110alpha and p110delta indicate complementary functions in Akt/PKB activation depending on neuroblastoma stage. Evaluation of the expression of the different PI3K isoforms in each neuroblastoma patient could be crucial for the success of treatment with PI3K isoform specific inhibitors.

Methods
=======

Material
--------

Freshly frozen tumor samples from patients diagnosed with neuroblastoma were staged according to the International Neuroblastoma Staging System Criteria (INSS) and International Neuroblastoma Risk Group (INRG) (Table [1](#T1){ref-type="table"}). These were mainly post-treatment neuroblastomas, clinical data according to Table [1](#T1){ref-type="table"}. The collection of material and subsequent study of the tissue material has been approved by the Karolinska University Hospital Research Ethics Committee (approval 03-736 and 2009/1369).

###### 

Clinical data

   **Patient**   **INSS**   **INRG**   **Age at diagnosis (months)**   **Follow up or outcome change (months)**   **Outcome**   **1p loss**   **MNA**   **11q loss**        **Origin**
  ------------- ---------- ---------- ------------------------------- ------------------------------------------ ------------- ------------- --------- -------------- -----------------------
      26R9          1          L                     2                                    91                          NED           neg         neg         neg            Adrenal gland
      25R9          2          L                    111                                   95                          NED           neg         neg         neg                 NA
      20R9          2          L                     3                                   113                          NED           neg         neg          NA                 NA
      27R7          2          L                     0                                    92                          NED           neg         neg         neg        Intraspinal abdominal
      33R7          2          L                     3                                    92                          NED           neg         neg         neg                 NA
      13E8          2          L                    32                                   202                          NED           neg         neg         neg                 NA
      15E7          3          L                     0                                    0                           DSC           neg         neg         neg                 NA
      15E3          3          L                    12                                   195                          NED           neg         neg         neg                 NA
      25R0          3          L                     1                                    97                          NED           neg         neg         neg               Thorax
      13E6          3          L                    48                                    12                          DOD           pos         pos         pos                 NA
      11R4          3          L                    15                                    27                          DOD           pos         pos         neg                 NA
      10R8          3          L                    80                                    59                          DOD           neg         neg         pos                 NA
       9R9          3          L                    24                                    21                          DOD           pos         neg         pos                 NA
      10R2          4          M                    15                                    12                          DOD           pos         pos         neg                 NA
      15R3          4          M                    28                                    9                           DOD           pos         neg         pos            Adrenal gland
      34R0          4          M                    64                                    11                          DOD           neg         neg         neg              Abdominal
      17R2          4          M                    80                                    45                          DOD           neg         neg         pos                 NA
      26R8          4          M                    21                                    18                          DOD           pos         pos          NA                 NA
      28R8          4          M                    29                                    26                          DOD           neg         neg         pos            Adrenal gland
      16E9          4          M                    19                                    5                           DOD           neg         pos         neg                 NA
      39R1          4          M                    22                                    29                          NED           pos         pos         neg              Abdominal

Abbreviations: *INSS*, International neuroblastoma staging system; *INRG*, International neuroblastoma risk group; *MNA*, MYCN amplification; *NA*, Information not available; *L*, Localized; *M*, Metastasized; *NED*, No evidence of disease; *DOD*, Dead of disease; *DSC*, Dead by surgical complications; *pos*, Positive; *neg*, Negative.

The neuroblastoma cell lines SK-N-AS, SK-N-BE(2), NB69, SH-SY-5Y, SK-N-F1, SK-N-DZ together with HeLa (cervical cancer) and colon cancer cell lines HT29 and COLO205 were obtained from ECACC while DAOY (medulloblastoma), OVCAR3 (ovary adenocarcinoma) and MDA-MB-468 (breast carcinoma) were obtained from ATCC. SUM190 was a kind gift from Dr. Shubbar, Gothenburg University, Sweden. Previous genomic profiling of neuroblastoma cell lines shows that SK-N-BE(2) and SK-N-DZ have *MYCN* amplification and that SH-SY-5Y and NB69 have 2p-gain, while SK-N-F1 and SK-N-AS is copy neutral \[[@B23]\]. The cell lines were cultured according to standard procedures in DMEM, supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin, before protein extraction according standard protocols.

Immunoblotting
--------------

Tumors were homogenized using Tissuelyzer (Qiagen) in RIPA lysis buffer supplemented with HALT™ Phosphatase and protease inhibitor cocktail (Pierce, Rockford, IL). A ready-made protein lysate for normal adrenal gland (20 pooled donors) was purchased from Clontech (Mountain View, CA).

SDS-PAGE and Western blot were carried out according to standard procedures using 30 μg of total protein lysate. Immunoblotting was performed with rabbit polyclonal antibodies against AKT1/2/3 (sc-8312) p-Akt (S473) (sc-7985-R), p-Akt (T308) (sc-16646-R), PTEN (sc-7974), GAPDH (sc-25778), and p110δ (sc-7176) obtained from Santa Cruz Biotechnology (Santa Cruz, CA), pan-p85 (\#06-496) from Millipore (Billerica, MA) while antibodies against p55γ (\#11889), p110α (\#4249) and p110β (\#3011) were obtained from Cell Signaling Technology. Quantification of proteins was performed with the ImageJ software \[[@B24]\]. GAPDH was used for normalization in calculation of relative expression. The logarithms of expression levels were calculated and the difference between groups was assessed by a two-tailed independent-samples *t*-test. Correlations were calculated using Pearson bivariate analysis using the SPSS version 18.0 software (SPSS, Inc.).
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###### Additional file 1

**Protein levels based on MYCN amplification or age at diagnosis.** Boxplot explanation; upper hinge of the box, 75^th^ percentile; lower hinge of the box, 25^th^ percentile; thick horizontal line within box, median. The whiskers are indicating range, open circles represent outliers while asterisks represent extremes.
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###### Additional file 2

**mRNA expression levels of STAT3. STAT3 show higher mRNA expression in stage 1 tumors compared to stage 4 tumors.** Boxplot derived from the R2: microarray analysis and visualization platform (<http://r2.amc.nl>).
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